ROS/Thermo dual-sensitive hydrogel loaded with a nanoemulsion of patchouli essential oil for ulcerative colitis

• Published in: International journal of biological macromolecules 2024-11, Vol.281 (Pt 4), p.136542, Article 136542
• Main Authors: Huang, You, Wang, Pei, Zhao, Pengyu, Cheng, Weijian, Fu, Hao, Zheng, Xiao, Chen, Lin, Huang, Wenyi, Xu, Jiajia, Fu, Chaomei, Zhang, Zhen, Wang, Xiao
• Format: Article
• Language: English
• Subjects: Administration, Rectal; Animals; Claudin-1 - metabolism; Colitis, Ulcerative - metabolism; Colitis, Ulcerative - therapy; Emulsions - administration & dosage; Hydrogels - administration & dosage; Male; Mice; Mice, Inbred ICR; Nanostructures - administration & dosage; Occludin - metabolism; Oils, Volatile - administration & dosage; Patchouli essential oil; Pogostemon; Polysaccharides - administration & dosage; RAW 264.7 Cells; Reactive oxygen species; Reactive Oxygen Species - metabolism; Ulcerative colitis
• ISSN: 0141-8130; 1879-0003; 1879-0003
• DOI: 10.1016/j.ijbiomac.2024.136542

Patchouli essential oil (PEO) is acknowledged as a potent contender for the management of ulcerative colitis (UC). However, the limited ability of PEO to be absorbed by the body and its low stability substantially limit its potential uses. Furthermore, UC lesions are mainly concentrated in the rectal and colonic mucosa, with excessive production of reactive oxygen species (ROS). Herein, a nanoemulsion of PEO (PEONE) was developed to enhance the stability and bioavailability of a drug. Subsequently, we developed a novel platform for the rectal administration of a ROS/thermo dual-sensitive Bletilla striata polysaccharide-based hydrogel (RTH) co-loaded with PEONE to efficiently treat UC. As expected, the sol–gel transition of PEONE@RTH, after its intrarectal administration, resulted in its extended presence in the colon and facilitated its attachment to the inflammation site. Moreover, PEONE@RTH alleviated dextran sulfate sodium-induced UC symptoms by suppressing inflammation and oxidative stress, repairing the damage to the intestinal epithelial barrier (claudin-1 and occludin), increasing short-chain fatty acid content and inhibiting the MAPK signalling pathway. Additionally, PEONE@RTH exhibits exceptional safety and biocompatibility. Thus, PEONE@RTH has the potential to provide a novel approach for treating UC and other intestinal disorders characterised by similar clinical conditions.